-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
ELV:NYE- (USD)
COMMON STOCK | Healthcare Plans |
Last Closing
USD 534.32Change
-0.97 (-0.18)%Market Cap
USD 122.56BVolume
0.66MVerdict
Verdict
Values as of: 2024-06-26
COMMON STOCK | Healthcare Plans |
Last Closing
USD 534.32Change
-0.97 (-0.18)%Market Cap
USD 122.56BVolume
0.66MVerdict
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
UNH | UnitedHealth Group Incorporate.. |
+22.82 (+4.69%) |
USD 445.93B |
CI | Cigna Corp |
-3.58 (-1.07%) |
USD 96.58B |
CVS | CVS Health Corp |
+0.70 (+1.20%) |
USD 75.60B |
HUM | Humana Inc |
+10.67 (+2.94%) |
USD 42.84B |
CNC | Centene Corp |
-1.07 (-1.59%) |
USD 36.14B |
MOH | Molina Healthcare Inc |
-5.53 (-1.83%) |
USD 17.82B |
OSCR | Oscar Health Inc |
-1.83 (-10.37%) |
USD 4.56B |
NEUE | NeueHealth Inc |
+0.24 (+4.62%) |
USD 0.05B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
FHI:CA | CI Health Care Giants Cov.. | 5.43 % | 0.75 % |
-0.06 (0.26%) |
CAD 0.09B |
ZWHC:CA | BMO Covered Call Health C.. | 4.88 % | 0.00 % |
-0.11 (0.26%) |
CAD 0.01B |
WHCS:SW | iShares MSCI World Health.. | 3.80 % | 0.00 % |
N/A |
USD 0.78B |
CBUF:F | iShares V Public Limited .. | 3.62 % | 0.00 % |
-0.02 (0.26%) |
USD 1.13B |
PBI:CA | Purpose Best Ideas | 3.49 % | 0.79 % |
N/A |
CAD 0.01B |
AILV | 3.21 % | 0.00 % |
N/A |
N/A | |
WELG:XETRA | Amundi S&P Global Health .. | 2.62 % | 0.00 % |
+0.04 (+0.26%) |
USD 0.25B |
WELS:XETRA | Amundi S&P Global Health .. | 2.62 % | 0.00 % |
+0.05 (+0.26%) |
USD 0.25B |
ESGI:AU | VanEck MSCI International.. | 2.57 % | 0.00 % |
+0.39 (+0.26%) |
USD 0.19B |
UBUS:F | UBS (Irl) ETF Public Limi.. | 2.33 % | 0.00 % |
N/A |
USD 0.25B |
UBUW:F | UBS (Irl) ETF Public Limi.. | 2.33 % | 0.00 % |
+0.03 (+0.26%) |
USD 0.02B |
UBUS:XETRA | UBS (Irl) ETF plc - Facto.. | 2.33 % | 0.00 % |
+0.19 (+0.26%) |
USD 0.49B |
UBUW:XETRA | UBS (Irl) ETF plc - Facto.. | 2.33 % | 0.00 % |
+0.17 (+0.26%) |
USD 0.05B |
UPVLE:SW | UBS (Irl) ETF plc - Facto.. | 2.33 % | 0.00 % |
N/A |
USD 0.02B |
UPVLD:SW | UBS (Irl) ETF plc - Facto.. | 2.33 % | 0.00 % |
+0.32 (+0.26%) |
USD 0.31B |
UPVLH:SW | UBS (Irl) ETF plc - Facto.. | 2.33 % | 0.00 % |
N/A |
USD 8.60M |
H41D:XETRA | HSBC MSCI World Value ESG.. | 2.17 % | 0.00 % |
+0.16 (+0.26%) |
USD 0.20B |
CBUI:XETRA | iShares MSCI World Value .. | 1.90 % | 0.00 % |
+0.03 (+0.26%) |
USD 0.26B |
XWBS:LSE | Xtrackers MSCI World Mini.. | 1.67 % | 0.00 % |
+0.11 (+0.26%) |
USD 0.01B |
ZUH:CA | BMO Equal Weight US Healt.. | 1.62 % | 0.39 % |
-0.37 (0.26%) |
CAD 0.29B |
KRUZ | 1.49 % | 0.00 % |
N/A |
N/A | |
DFUV | Dimensional US Marketwide.. | 1.18 % | 0.00 % |
+0.21 (+0.26%) |
USD 10.31B |
DFLV | Dimensional ETF Trust - D.. | 1.12 % | 0.00 % |
+0.20 (+0.26%) |
USD 1.73B |
PTL | Northern Lights Fund Trus.. | 0.98 % | 0.00 % |
+0.53 (+0.26%) |
N/A |
EVO:CA | Evovest Global Equity ETF | 0.95 % | 0.00 % |
+0.06 (+0.26%) |
CAD 0.02B |
IHF | iShares U.S. Healthcare P.. | 0.00 % | 0.43 % |
+0.32 (+0.26%) |
USD 0.75B |
HHL-U:CA | Harvest Healthcare Leader.. | 0.00 % | 0.00 % |
-0.05 (0.26%) |
N/A |
FHI-B:CA | CI Health Care Giants Cov.. | 0.00 % | 0.00 % |
N/A |
CAD 0.05B |
RYH | 0.00 % | 0.40 % |
N/A |
N/A | |
XHS | SPDR® S&P Health Care Se.. | 0.00 % | 0.35 % |
-0.27 (0.26%) |
USD 0.08B |
HHL:CA | Harvest Healthcare Leader.. | 0.00 % | 1.15 % |
-0.05 (0.26%) |
CAD 0.33B |
UC96:LSE | UBS (Irl) ETF plc - Facto.. | 0.00 % | 0.00 % |
+17.50 (+0.26%) |
USD 0.26B |
UPVL:LSE | UBS (Irl) ETF plc - Facto.. | 0.00 % | 0.00 % |
+10.75 (+0.26%) |
USD 8.56M |
TEQI | T. Rowe Price Equity Inco.. | 0.00 % | 0.00 % |
+0.04 (+0.26%) |
USD 0.16B |
CBUF:XETRA | iShares MSCI World Health.. | 0.00 % | 0.00 % |
+0.02 (+0.26%) |
USD 1.13B |
HHL-B:CA | Harvest Healthcare Leader.. | 0.00 % | 0.00 % |
-0.08 (0.26%) |
N/A |
TDOC:CA | TD Global Healthcare Lead.. | 0.00 % | 0.00 % |
-0.06 (0.26%) |
CAD 0.08B |
Market Performance vs. Industry/Classification (Healthcare Plans) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 13.31% | 88% | B+ | 83% | B | ||
Dividend Return | 0.69% | 40% | F | 21% | F | ||
Total Return | 14.00% | 88% | B+ | 81% | B- | ||
Trailing 12 Months | |||||||
Capital Gain | 22.24% | 75% | C | 80% | B- | ||
Dividend Return | 1.42% | 40% | F | 20% | F | ||
Total Return | 23.66% | 75% | C | 79% | B- | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 0.35% | 13% | F | 42% | F | ||
Dividend Return | 0.83% | 13% | F | 33% | F | ||
Total Return | 0.48% | 20% | F | 11% | F | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 7.29% | 100% | F | 84% | B | ||
Risk Adjusted Return | 11.39% | 13% | F | 36% | F | ||
Market Capitalization | 122.56B | 89% | A- | 98% | N/A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The company has under performed its peers on annual average total returns in the past 5 years.
This stock has shown below median dividend growth in the previous 5 years compared to its sector.